XORTX Announces Topline Results From XRX-OXY-101 Clinical Trial
XORTX Therapeutics Inc. ("XORTX" or the "Company") (NASDAQ:XRTX, TSXV:XRTX, Frankfurt: ANU)))), a late-stage clinical pharmaceutical company focused on developing innovative therapies to treat
XORTX Announces Completion Of Screening And Enrollment In Bridging Pharmacokinetics Study
XORTX Therapeutics Inc. ("XORTX" or the “Company”) (NASDAQ:XRTX, TSXV:XRTX, Frankfurt: ANU)), a late-stage clinical pharmaceutical company focused on developing innovative therapies to treat
XORTX Announces $5M Public Offering
XORTX Therapeutics Inc. ("XORTX" or the “Company”) (NASDAQ:XRTX, TSXV:XRTX, Frankfurt: ANU)), a late stage clinical pharmaceutical company focused on developing innovative therapies to treat
XORTX Files New PCT Patent To Treat And Protect Individuals Most At Risk To Severe Viral Infection
XORTX Therapeutics Inc. ("XORTX" or the “Company”) (NASDAQ:XRTX, TSXV:XRTX, Frankfurt: ANU)), a pharmaceutical therapeutics company focused on developing innovative therapies to treat progressive